Search company, investor...

Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
lumiraventures.com

Investments

163

Portfolio Exits

40

Funds

3

About Lumira Ventures

Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meeting significant unmet needs and creating transformation impact in communities worldwide. Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.

Headquarters Location

141 Adelaide St. W. Ste. 770

Ontario, M5H 3L5,

Canada

416-213-4223

Want to inform investors similar to Lumira Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Lumira Ventures News

08:00 ET DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

Jun 13, 2023

News provided by Share this article Share this article TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. John Reilly is the new Chief Executive Officer of DAMONA Pharmaceuticals Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business development, and leading teams in preclinical R&D and clinical development of innovative therapies. "We feel very fortunate to have attracted John into the role of CEO for Damona. He brings a wealth of biotechnology company-building experience and a vast network of North American investor and partner relationships, which will be essential in bringing our lead asset toward IND and clinical human proof-of-concept trials," said Etienne Sibille, Ph.D., Co-Founder and Chief Scientific Officer of DAMONA. "I'm ecstatic to have John join the DAMONA team as CEO. John brings a great background to DAMONA with a proven track record of building and managing high-performance preclinical and clinical biopharmaceutical teams that deliver results," said Jacki Jenuth, Partner and Chief Operating Officer of Lumira Ventures. Prior to joining DAMONA, Mr. Reilly co-founded and served as President and CEO of Apic Bio, a gene therapy company developing first-in-class treatments for rare neurological and liver diseases. At Apic, he secured multiple funding rounds, oversaw development programs, and orchestrated a global licensing agreement with uniQure for the company's lead program to treat superoxide dismutase 1 (SOD1), a rare, genetic form of ALS. Previously, Mr. Reilly held a number of senior management positions at various biopharmaceutical companies, including Vice President of Business Development at Tetragenetics, which was acquired by Abcellera (Nasdaq: ABCL ). Prior to Tetragenetics, he co-founded and served as CEO of Gendyne Therapeutics. Mr. Reilly holds a B.A. from Hamilton College and M.S. and M.B.A. degrees from Cornell University. "I am very excited to join DAMONA as CEO and look forward to working with the board, management, and scientific team to continue the company's impressive progress as we advance the preclinical pipeline and lead program for the treatment of cognitive symptoms associated with depression and diseases of aging into a Phase 1 clinical study," said John Reilly, CEO of DAMONA Pharmaceuticals. About DAMONA Pharmaceuticals DAMONA is a privately held preclinical biopharmaceutical company developing small molecule therapeutics that transform the treatment of cognitive deficits and restore normal brain functions for underserved and understudied mental health conditions and for aging populations. DAMONA was founded by Etienne Sibille, Ph.D., and the Centre for Addiction and Mental Health (CAMH). In 2022, DAMONA closed a seed financing round co-led by Lumira Ventures and the Noetic Fund. For more information, please visit: www.damonapharma.com . Contact:

Lumira Ventures Investments

163 Investments

Lumira Ventures has made 163 investments. Their latest investment was in GenEp as part of their Seed VC - II on May 5, 2023.

CBI Logo

Lumira Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/31/2023

Seed VC - II

GenEp

$4.96M

Yes

1

4/27/2023

Series E

Antiva Biosciences

$53M

No

5

2/28/2023

Series B

Cadence Neuroscience

$26.03M

Yes

4

1/12/2023

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

1/5/2023

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/31/2023

4/27/2023

2/28/2023

1/12/2023

1/5/2023

Round

Seed VC - II

Series E

Series B

Series A - II

Series D

Company

GenEp

Antiva Biosciences

Cadence Neuroscience

Subscribe to see more

Subscribe to see more

Amount

$4.96M

$53M

$26.03M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

5

4

10

10

Lumira Ventures Portfolio Exits

40 Portfolio Exits

Lumira Ventures has 40 portfolio exits. Their latest portfolio exit was enGene on May 17, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/17/2023

Acq - Pending

$99M

2

8/6/2021

Acquired

$99M

15

6/5/2020

Acquired

$99M

6

9/13/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/7/2019

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/17/2023

8/6/2021

6/5/2020

9/13/2019

6/7/2019

Exit

Acq - Pending

Acquired

Acquired

IPO

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

15

6

10

10

Lumira Ventures Fund History

3 Fund Histories

Lumira Ventures has 3 funds, including Lumira Capital IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/26/2021

Lumira Capital IV

$220M

5

Lumira Capital II

$99M

10

Merck-Lumira Biosciences Fund

$99M

10

Closing Date

7/26/2021

Fund

Lumira Capital IV

Lumira Capital II

Merck-Lumira Biosciences Fund

Fund Type

Status

Amount

$220M

$99M

$99M

Sources

5

10

10

Lumira Ventures Team

6 Team Members

Lumira Ventures has 6 team members, including current Founder, Managing Partner, Peter van der Velden.

Name

Work History

Title

Status

Peter van der Velden

Canadian Venture Capital and Private Equity Association, MDS Capital, Fusion Capital, Taurus Capital, and Bedford Capital

Founder, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Peter van der Velden

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Canadian Venture Capital and Private Equity Association, MDS Capital, Fusion Capital, Taurus Capital, and Bedford Capital

Title

Founder, Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.